|
🐬
|
Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
R. Parisi,
D. Symmons,
C. Griffiths,
D. Ashcroft
|
11 |
2013 |
11
🐬
|
|
🦁
|
Pathogenesis and clinical features of psoriasis
C. Griffiths,
J. Barker
|
10 |
2007 |
10
🦁
|
|
🐜
|
Secukinumab in plaque psoriasis--results of two phase 3 trials.
20 auth.
R. Langley,
B. Elewski,
M. Lebwohl,
K. Reich,
C. Griffiths,
K. Papp,
L. Puig,
H. Nakagawa,
L. Spelman,
B. Sigurgeirsson,
...
E. Rivas,
T. Tsai,
N. Wasel,
S. Tyring,
T. Salko,
I. Hampele,
M. Notter,
A. Karpov,
S. Helou,
C. Papavassilis
|
10 |
2014 |
10
🐜
|
|
🐢
|
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
9 auth.
K. Reich,
F. Nestle,
K. Papp,
J. Ortonne,
R. Evans,
C. Guzzo,
...
Shu Li,
L. T. Dooley,
C. Griffiths
|
10 |
2005 |
10
🐢
|
|
🐢
|
Psoriasis: epidemiology, clinical features, and quality of life
R. Langley,
G. Krueger,
C. Griffiths
|
10 |
2005 |
10
🐢
|
|
🐜
|
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
84 auth.
A. Strange,
F. Capon,
C. Spencer,
J. Knight,
M. Weale,
M. Allen,
A. Barton,
G. Band,
C. Bellenguez,
Judith G. M. Bergboer,
J. Blackwell,
E. Bramon,
S. Bumpstead,
J. Casas,
M. J. Cork,
...
A. Corvin,
P. Deloukas,
A. Dilthey,
A. Duncanson,
S. Edkins,
X. Estivill,
O. FitzGerald,
C. Freeman,
E. Giardina,
Emma V. Gray,
A. Hofer,
U. Hüffmeier,
S. Hunt,
A. Irvine,
Janusz Jankowski,
B. Kirby,
C. Langford,
J. Lascorz,
J. Leman,
S. Leslie,
L. Mallbris,
H. Markus,
C. Mathew,
W. Mclean,
R. McManus,
R. Mössner,
L. Moutsianas,
Å. T. Naluai,
F. Nestle,
G. Novelli,
A. Onoufriadis,
C. Palmer,
C. Perricone,
M. Pirinen,
R. Plomin,
Simon C. Potter,
R. Pujol,
A. Rautanen,
E. Riveira-Muñoz,
A. Ryan,
W. Salmhofer,
L. Samuelsson,
S. Sawcer,
J. Schalkwijk,
Catherine H. Smith,
M. Ståhle,
Z. Su,
R. Tazi-Ahnini,
H. Traupe,
A. Viswanathan,
R. Warren,
W. Weger,
Katarina Wolk,
N. Wood,
Jane Worthington,
H. Young,
P. Zeeuwen,
A. Hayday,
A. Burden,
C. Griffiths,
J. Kere,
A. Reis,
G. McVean,
David M. Evans,
M. Brown,
J. Barker,
L. Peltonen,
P. Donnelly,
R. Trembath
|
9 |
2010 |
9
🐜
|
|
🦁
|
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
13 auth.
C. Griffiths,
B. Strober,
P. C. van de Kerkhof,
V. Ho,
R. Fidelus-Gort,
N. Yeilding,
C. Guzzo,
Yichuan Xia,
Bei Zhou,
Shu Li,
...
L. T. Dooley,
N. H. Goldstein,
A. Menter
|
9 |
2010 |
9
🦁
|
|
🦁
|
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
16 auth.
C. Griffiths,
K. Reich,
M. Lebwohl,
P. Kerkhof,
C. Paul,
A. Menter,
G. Cameron,
J. Erickson,
Lu Zhang,
R. Secrest,
...
S. Ball,
D. Braun,
O. Osuntokun,
M. Heffernan,
B. Nickoloff,
K. Papp
|
9 |
2015 |
9
🦁
|
|
🐬
|
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
R. Parisi,
I. Iskandar,
E. Kontopantelis,
M. Augustin,
C. Griffiths,
D. Ashcroft
|
9 |
2020 |
9
🐬
|
|
🐜
|
Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial
8 auth.
A. Blauvelt,
K. Papp,
C. Griffiths,
B. Randazzo,
Y. Wasfi,
Yaung-Kaung Shen,
...
Shu Li,
A. Kimball
|
9 |
2017 |
9
🐜
|
|
🐜
|
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
200 auth.
L. Tsoi,
S. Spain,
J. Knight,
E. Ellinghaus,
P. Stuart,
F. Capon,
Jun Ding,
Yun Li,
T. Tejasvi,
J. Gudjonsson,
H. Kang,
M. Allen,
R. McManus,
G. Novelli,
L. Samuelsson,
...
J. Schalkwijk,
M. Ståhle,
A. Burden,
Catherine H. Smith,
M. J. Cork,
X. Estivill,
A. Bowcock,
G. Krueger,
W. Weger,
Jane Worthington,
R. Tazi-Ahnini,
F. Nestle,
A. Hayday,
P. Hoffmann,
J. Winkelmann,
C. Wijmenga,
C. Langford,
S. Edkins,
R. Andrews,
H. Blackburn,
A. Strange,
R. Pearson,
Damjan Vukcevic,
C. Spencer,
P. Deloukas,
U. Mrowietz,
S. Schreiber,
S. Weidinger,
S. Kõks,
K. Kingo,
T. Esko,
A. Metspalu,
H. Lim,
J. Voorhees,
M. Weichenthal,
H. Wichmann,
V. Chandran,
C. Rosen,
P. Rahman,
D. Gladman,
C. Griffiths,
A. Reis,
J. Kere,
R. P. Nnair,
A. Franke,
J. Barker,
G. Abecasis,
J. T. Eelder,
R. Ttrembath,
K. Duffin,
C. Helms,
D. Goldgar,
J. Paschall,
M. Malloy,
C. Pullinger,
J. Kane,
Jennifer M. Gardner,
A. Perlmutter,
A. Miner,
B. Feng,
R. Hiremagalore,
R. Ike,
E. Christophers,
T. Henseler,
A. Ruether,
Steven J. Schrodi,
S. Prahalad,
S. Guthery,
J. Fischer,
W. Liao,
P. Kwok,
A. Menter,
G. Lathrop,
C. Wise,
A. Begovich,
A. Onoufriadis,
M. Weale,
A. Hofer,
W. Salmhofer,
P. Wolf,
Kati Kainu,
U. Saarialho-Kere,
S. Suomela,
P. Badorf,
U. Hüffmeier,
W. Kurrat,
W. Küster,
J. Lascorz,
R. Mössner,
F. Schürmeier-Horst,
M. Ständer,
H. Traupe,
Judith G. M. Bergboer,
M. Heijer,
P. Kerkhof,
P. Zeeuwen,
L. Barnes,
L. Campbell,
C. Cusack,
C. Coleman,
J. Conroy,
S. Ennis,
O. FitzGerald,
P. Gallagher,
A. Irvine,
B. Kirby,
T. Markham,
W. Mclean,
J. Mcpartlin,
S. Rogers,
A. Ryan,
A. Zawirska,
E. Giardina,
T. Lepre,
C. Perricone,
G. Martin-Ezquerra,
R. Pujol,
E. Riveira-Muñoz,
A. Inerot,
Å. T. Naluai,
L. Mallbris,
K. Wolk,
J. Leman,
A. Barton,
R. Warren,
H. Young,
I. Ricaño-Ponce,
G. Trynka,
F. Pellett,
A. Henschel,
M. Aurand,
B. Bebo,
C. Gieger,
T. Illig,
S. Moebus,
K. Jöckel,
R. Erbel,
P. Donnelly,
L. Peltonen,
J. Blackwell,
E. Bramon,
M. Brown,
J. Casas,
A. Corvin,
N. Craddock,
A. Duncanson,
Janusz Jankowski,
H. Markus,
C. Mathew,
M. McCarthy,
C. Palmer,
R. Plomin,
A. Rautanen,
S. Sawcer,
N. Samani,
A. Viswanathan,
N. Wood,
C. Bellenguez,
C. Freeman,
G. Hellenthal,
E. Giannoulatou,
M. Pirinen,
Z. Su,
S. Hunt,
R. Gwilliam,
S. Bumpstead,
S. Dronov,
M. Gillman,
Emma V. Gray,
Naomi Hammond,
Alagurevathi Jayakumar,
O. T. McCann,
J. Liddle,
M. L. Pérez,
Simon C. Potter,
Radhi Ravindrarajah,
M. Ricketts,
M. Waller,
P. Weston,
S. Widaa,
P. Whittaker,
R. Neir,
J. Barker,
James T. Elder,
R. Trembath
|
9 |
2012 |
9
🐜
|
|
🐢
|
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
12 auth.
K. Papp,
K. Reich,
C. Leonardi,
L. Kircik,
S. Chimenti,
R. Langley,
...
ChiaChi Hu,
R. Stevens,
R. Day,
K. Gordon,
N. Korman,
C. Griffiths
|
9 |
2015 |
9
🐢
|
|
🐜
|
Identification of fifteen new psoriasis susceptibility loci highlights the role of innate immunity
65 auth.
L. Tsoi,
S. Spain,
J. Knight,
E. Ellinghaus,
P. Stuart,
F. Capon,
Jun Ding,
Yanming Li,
T. Tejasvi,
J. Gudjonsson,
H. Kang,
M. Allen,
R. McManus,
G. Novelli,
L. Samuelsson,
...
J. Schalkwijk,
M. Ståhle,
A. Burden,
Catherine H. Smith,
M. J. Cork,
X. Estivill,
A. Bowcock,
G. Krueger,
W. Weger,
Jane Worthington,
R. Tazi-Ahnini,
F. Nestle,
A. Hayday,
P. Hoffmann,
J. Winkelmann,
C. Wijmenga,
C. Langford,
S. Edkins,
R. Andrews,
H. Blackburn,
A. Strange,
G. Band,
R. Pearson,
Damjan Vukcevic,
C. Spencer,
P. Deloukas,
U. Mrowietz,
S. Schreiber,
S. Weidinger,
S. Kõks,
K. Kingo,
T. Esko,
A. Metspalu,
H. Lim,
J. Voorhees,
M. Weichenthal,
H. Wichmann,
V. Chandran,
C. Rosen,
P. Rahman,
D. Gladman,
C. Griffiths,
A. Reis,
J. Kere,
R. Nair,
A. Franke,
J. Barker,
G. Abecasis,
James T. Elder,
R. Trembath
|
8 |
2012 |
8
🐜
|
